Kaleido Signs a Collaboration with Janssen for Microbiome Metabolic Therapies (MMT)

Janssen’s Darzalex (daratumumab) Receives MHLW’s Approval for Transplant Ineligible Patients with Multiple Myeloma in Japan


  • Janssen’s World Without Disease Accelerator partners with Kaleido to evaluate its MMT involved in prevention of the onset of childhood allergy including atopic, immune and metabolic conditions
  • The focus of the agreement is to utilize Kaleido’s proprietary ex vivo screening platform to identify MMTs therapies for the growth of microbes and further will be evaluated to prevent atopic conditions including infant allergy
  • MMTs are targeted glycans orally administered utilizes Kaleido’s human-centric discovery and development platform and is evaluated to study its safety, efficacy, tolerability and potential markers of effect

Click here to read full press release/ article | Ref: Kaleido Biosciences | Image: Behance